|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-16
|
|
pubmed:abstractText |
Recent studies have shown that prescription rates and doses of recommended drugs for chronic heart failure (CHF) are not optimal in daily practice. The aim of the Impact-Reco programme was to analyse prescription rates of CHF drugs in stable outpatients with CHF related to left ventricular (LV) systolic dysfunction in two similar surveys in France.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1388-9842
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
85-91
|
|
pubmed:dateRevised |
2011-6-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19147461-Adrenergic beta-Antagonists,
pubmed-meshheading:19147461-Angiotensin Receptor Antagonists,
pubmed-meshheading:19147461-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:19147461-Chronic Disease,
pubmed-meshheading:19147461-Comorbidity,
pubmed-meshheading:19147461-France,
pubmed-meshheading:19147461-Guideline Adherence,
pubmed-meshheading:19147461-Health Care Surveys,
pubmed-meshheading:19147461-Heart Failure,
pubmed-meshheading:19147461-Humans,
pubmed-meshheading:19147461-Physician's Practice Patterns,
pubmed-meshheading:19147461-Practice Guidelines as Topic,
pubmed-meshheading:19147461-Spironolactone
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme.
|
|
pubmed:affiliation |
Pôle de Cardiologie et Maladies Vasculaires, CHRU de Lille, Université de Lille 2, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
